DFTX Definium Therapeutics, Inc.

Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward late-stage and commercial-stage names. All three of the highlighted stocks are positioned to launch products with significant peak sales potential.

Definium Therapeutics (NASDAQ:DFTX) Chief Medical Officer Dan Karlin said the company’s recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder, or GAD, and major depressive disorder, or MDD, following a single treatment, with longer-term open

Key Takeaways; Psychedelic Sector Optimi Health Plans to Initiate Phase 3 Clinical Trial Evaluating MDMA Therapy for Individuals with PTSD Eli Lilly Completed $2.8 Billion Acquisition of AtaiBeckley, Expanding its Mental Health Pipeline Definium’s Phase 3 Panorama Trial Delivered Positive Results for DT120 in Generalized Anxiety Disorder Psyence BioMed Established Texas Entity to Advance U.S. […]

Definium Therapeutics, Inc. (NASDAQ:DFTX) has now delivered a third consecutive positive Phase 3 readout for its LSD-based medication, the second in generalized anxiety disorder. The result puts the company on a viable route toward a potential FDA approval of an LSD-based treatment for generalized anxiety disorder, and considering how closely psychedelic stocks have historically traded on […]

Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder, or GAD. The company said the single-dose treatment met its primary endpoint and all key secondary endpoints, adding to positive pivo

Large-cap healthcare outperformed this week: XLV gained 1.4% through Tuesday, while XBI fell 1.4% and IBB declined 0.5%.

DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.

Definium Therapeutics has ridden a powerful three year run, and that surge now puts a spotlight on a simple question for investors who care about balance sheets. Is the current share price still grounded in what the business is worth on its books, or has sentiment pulled it away from its underlying equity value? Over the past three years, Definium Therapeutics has delivered a return of roughly 8.9x, which raises the stakes for whether the stock price still lines up with the value recorded on...

Definium Therapeutics plans to submit an NDA for DT120 in GAD In the first half of 2027.

Definium Therapeutics recently reported that its Phase 3 Panorama trial of DT120, an LSD-based orally disintegrating tablet, in adults with generalized anxiety disorder met the primary and all key secondary endpoints, with a single 100 µg dose delivering a statistically significant 5.1‑point placebo‑adjusted reduction in HAM‑A anxiety scores at Week 12. The data also showed early and durable symptom relief from just one treatment, with meaningful improvements as soon as Day 2 and no new...

Definium Therapeutics (DFTX) just reported that its second Phase 3 Panorama trial of DT120 ODT in generalized anxiety disorder met primary and key secondary endpoints, with clinically meaningful, placebo adjusted improvements in anxiety measures. Definium Therapeutics shares have rallied strongly, with a 90 day share price return of 66.6% and a year to date share price gain of 195.09%. The 1 year total shareholder return of 321.47% signals powerful momentum that the latest Phase 3 success...

Definium Therapeutics' LSD eased the symptoms of anxiety, the company said Monday as shares took off again.

Definium Therapeutics advances the case for medical LSD after reporting positive late-stage trial data for its experimental drug, DT120.

Healthcare stocks advanced Monday afternoon, with the NYSE Healthcare Index up 1.6% and the State St

The company said that the Panorama trial of DT120, a fast-dissolving tablet form of the psychedelic drug lysergide, or LSD, met its main goal in adults with generalized anxiety disorder.

All three major US stock indexes were down in late-morning trading Monday, as major artificial intel

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares rose 20% after the company reported topline results from its Phase 3 Panorama study evaluating DT120 ODT in patients with generalized anxiety disorder.

Investors are awaiting topline results from Panorama, its second Phase 3 trial of DT120 in generalized anxiety disorder, set to be unveiled on Monday.

Stanley Druckenmiller’s Duquesne Family Office recently filed its 13F for the second quarter. The firm opened new stakes in more than 40 stocks. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) and Definium Therapeutics, Inc. (NASDAQ:DFTX) are the notable ones in the healthcare space. Duquesne bought 203,618 shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) worth $22.6 million. The fund also […]

Key Takeaways; Cannabis Sector Curaleaf Holdings Announced Intention to Launch a Hostile Takeover Bid to Acquire Aurora Cannabis Organigram Posted Record Quarter as Sanity Group Acquisition Fueled Global Expansion Key Takeaways; Psychedelic Sector Optimi Health Set Up US$100 Million Equity Facility to Support Growth Definium Therapeutics’ Phase 3 Trial Delivered Strong Results for DT120 in […]

Definium Therapeutics (DFTX) is back in focus after reporting positive topline results from its Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder. This event has quickly refocused attention on the stock. See our latest analysis for Definium Therapeutics. Definium Therapeutics has been highly volatile over the past year, with the latest share price at $43.90 following a 1 day share price return of 2.59% after the Voyage update. Despite recent 7 day and 30 day share price...

In August 2026, Definium Therapeutics reported that its Phase 3 Voyage trial of DT120 ODT in generalized anxiety disorder met the primary HAM-A endpoint and all key secondary measures, delivering rapid, statistically significant symptom reductions with a generally well-tolerated safety profile and no new safety signals identified. Beyond the headline efficacy, the data point to a single 100 µg dose producing early-onset, sustained relief over 12 weeks, highlighting how Definium’s LSD-based,...

Definium Therapeutics (NasdaqGS: DFTX) reported positive topline data from its pivotal Phase 3 Voyage trial of DT120 ODT in adults with generalized anxiety disorder. The study met all primary and key secondary endpoints, with results indicating significant efficacy alongside a positive safety and tolerability profile. DT120 ODT, an LSD based oral dissolving tablet, holds Breakthrough Therapy designation and is now positioned for potential regulatory review in a major psychiatric...

Definium Therapeutics' (DFTX) phase 3 data for DT120 in generalized anxiety disorder looked better t

Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Voyage, its Phase III study evaluating a single 100 mcg dose of DT120 ODT for generalized anxiety disorder, or GAD. The company said the trial met its primary endpoint and all key secondary endpoints, showing rapid and durab

Definium Therapeutics unveiled the second of two positive Phase 3 studies for its LSD-based drug. The biotech stock rose on the results.

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t

Voyage is the company’s second successful late-stage readout for DT120, following positive results in major depressive disorder in June.

The S&P 500 Index and Nasdaq Composite were up slightly, while the Dow Jones Industrial Average was

Shares of Definium Therapeutics jumped more than 10% Wednesday morning after the biotech company said its experimental psychedelic drug helped reduce anxiety. DT120, a fast-dissolving tablet form of lysergide, was tested in a late-stage trial of 214 people with generalized anxiety disorder. Definium is also testing DT120 as a treatment for post-traumatic stress disorder.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2%, and the actively tra

Definium Therapeutics (NASDAQ:DFTX) shares jumped 20% in premarket trading on Wednesday after the company announced positive topline results from its Phase 3 Voyage study evaluating DT120 ODT in patients with generalised anxiety disorder. The trial achieved its primary endpoint as well as all key secondary efficacy endpoints, providing another positive late-stage clinical result for the company’s DT120 ODT development programme.

Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.

Definium Therapeutics, which develops treatments for mental health conditions, faces high expectations for its late-stage Voyage study of DT120.

Definium Therapeutics Inc (DFTX) reports the largest treatment effect ever seen in a Phase III MDD study while advancing its GAD program toward imminent top-line data.

Definium Therapeutics (NASDAQ:DFTX) said it expects to report top-line results from its Phase III VOYAGE study of DT120 ODT in generalized anxiety disorder during the week of Aug. 10, following positive Phase III results in major depressive disorder reported in June. Chief Executive Officer Rob Bar

The average of price targets set by Wall Street analysts indicates a potential upside of 34.9% in Definium Therapeutics, Inc. (DFTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. The U.S. market saw a strong rally in the second quarter, fueled by easing geopolitical tensions, falling oil prices, and robust corporate earnings. Growth stocks, especially in technology and […]

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.

Watch Fireside Chat Below, or Click HERE: IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. (Nasdaq: JUNS) Chairman, Chief Executive Officer and Co-founder Christer Rosén and Alison Silva, […]

Definium Therapeutics (DFTX) stock is drawing fresh attention after the company published a large healthcare claims analysis on generalized anxiety disorder, highlighting frequent treatment switching, early discontinuation, and long gaps in care with existing therapies. See our latest analysis for Definium Therapeutics. The recent healthcare claims study comes as Definium Therapeutics stock continues a strong run, with a 30 day share price return of 84.15% and a year to date share price...

Earlier this month, Definium Therapeutics reported results from a large U.S. healthcare claims study of more than 1.27 million adults with generalized anxiety disorder, showing high rates of treatment discontinuation, rapid switching, and prolonged gaps in pharmacotherapy despite guideline recommendations. The study, published in CNS Spectrums, underscores how fragmented guidance, frequent comorbid depression, and limited innovation since 2007 leave a substantial unmet need for...

Billionaire investors such as Peter Thiel and Christian Angermayer are believers in the benefits of using psychedelics derived from magic mushrooms...

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Definium Therapeutics, Inc. (NASDAQ:DFTX) is one of the best psychedelic stocks on our list. TheFly reported on June 30 that Canaccord reduced its price target on DFTX to $58 from $60 while reaffirming a Buy rating on the shares. The firm […]

An obscure psychedelic is drawing intense interest from the pharmaceutical industry. WSJ explores why companies are betting hundreds of millions of dollars on the therapeutic potential of a toad poison.

The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Definium Therapeutics, Inc. (DFTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.